Get access

Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists

Authors

  • Frank Andersohn MD,

    Corresponding author
    1. Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany
    • Bremen Institute for Prevention Research and Social Medicine, Linzer Str. 10, D-28359 Bremen, Germany
    Search for more papers by this author
  • Edeltraut Garbe MD, PhD

    1. Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany
    2. Institute of Clinical Pharmacology and Toxicology, Charité Universitaetsmedizin Berlin, Germany
    Search for more papers by this author

  • Potential conflict of interest: Frank Andersohn reports no financial support or conflicts of interest. Edeltraut Garbe reports receiving consulting fees and an unrestricted grant from Bayer Schering Healthcare AG.

Abstract

There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy. Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse. Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions. We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database. Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs). For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine). Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves. For nonergot-derived dopamine agonists, no drug safety signals were evident. © 2008 Movement Disorder Society

Ancillary